Xenon Nears Pivotal Epilepsy Data With $716M War Chest

VANCOUVER, BC and BOSTON, MA – February 26, 2026 – Xenon Pharmaceuticals has positioned itself for a transformative year, announcing in its latest financial report that pivotal data for its lead drug candidate, azetukalner, is expected in the first half of March. The neuroscience-focused company confirmed it is on track to release topline results from its Phase 3 X-TOLE2 study in patients with focal onset seizures (FOS), a critical step that could pave the way for a New Drug Application (NDA) with the U.S. Food and Drug Administration in the second half of 2026.

The announcement came as part of the company's fourth-quarter and full-year 2025 financial results, which revealed a significant ramp-up in spending to support its ambitious clinical programs. Despite posting a wider net loss, Xenon simultaneously unveiled a robust pro forma cash position of $716 million, securing its operational runway into the latter half of 2027 and underscoring its commitment to a high-stakes, multi-front clinical development strategy.

“2025 marked a period of significant momentum and strong execution across multiple Phase 3 clinical trials of azetukalner in epilepsy and neuropsychiatry, as well as our early-stage pipeline,” said Ian Mortimer, President and Chief Executive Officer of Xenon. “We’re looking forward to several upcoming milestones, starting with reporting topline data for our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures in the first half of March, followed by an anticipated NDA submission in the second half of this year.”

The Azetukalner Catalyst

At the heart of Xenon's strategy is azetukalner, a novel, potent KV7 potassium channel opener. This mechanism is designed to stabilize neurons and reduce the excessive electrical firing that underlies seizures. As the most clinically advanced KV7 modulator in late-stage development, it represents a potentially new class of therapy for epilepsy patients, many of whom fail to achieve adequate seizure control with existing treatments like levetiracetam or lamotrigine.

The upcoming X-TOLE2 data is the company's most immediate and significant catalyst. However, confidence is buoyed by impressive long-term results from an ongoing open-label extension (OLE) study. Data presented at the American Epilepsy Society (AES) annual meeting showed that among participants treated for four years or more, monthly seizure frequency was reduced by over 90% from their pre-treatment baseline. Perhaps more remarkably, over 38% of these long-term participants achieved at least 12 consecutive months of seizure freedom, a life-altering outcome for individuals with refractory epilepsy.

Should the X-TOLE2 study replicate this success in a controlled setting, azetukalner could become a highly anticipated new option in a crowded but still underserved market. The company is also pursuing an additional epilepsy indication for primary generalized tonic-clonic seizures (PGTCS) in its ongoing Phase 3 X-ACKT study, further broadening the drug's potential impact.

The Price of Innovation

Advancing a drug through six concurrent Phase 3 trials is a costly endeavor, a reality reflected in Xenon's 2025 financial statements. The company reported a significant increase in research and development (R&D) expenses, which surged to $300.9 million for the full year, up from $210.4 million in 2024. This aggressive investment drove the company's net loss to $345.9 million for 2025, compared to $234.3 million the previous year.

While such figures might alarm some, they are indicative of a clinical-stage biopharmaceutical company in the final, most expensive stages of drug development. To fuel this R&D engine, Xenon has been strategic in its financing. The company raised $242.2 million in net proceeds through its at-the-market (ATM) stock offering, including $130.0 million in the first quarter of 2026 alone. This has fortified its balance sheet, providing a pro forma cash position of $716 million.

This financial cushion is critical, as it provides a cash runway into the second half of 2027. This timeline comfortably covers several key upcoming milestones, including the X-TOLE2 data readout, the potential NDA submission for FOS, and the expected 2027 data release for azetukalner in major depressive disorder. This demonstrates a calculated strategy: absorb near-term losses to fund a pipeline with the potential for significant long-term returns, all while ensuring the financial stability to see it through.

Beyond Seizures: A Broadening Neuroscience Pipeline

Xenon's ambitions for azetukalner extend far beyond epilepsy. The company is evaluating the drug in two large Phase 3 programs for major depressive disorder (MDD) and another for bipolar depression (BPD). The scientific rationale is that the same neuronal-stabilizing mechanism of action could help regulate mood circuits. With topline data from the first MDD study, X-NOVA2, expected in the first half of 2027, azetukalner has the potential to become a true 'pipeline in a molecule,' addressing multiple major neurological and psychiatric conditions.

Further diversifying its portfolio, Xenon is leveraging its deep expertise in ion channel biology to tackle the immense and challenging pain market. The company is advancing two early-stage candidates, XEN1701 and XEN1120, with Phase 1 data expected in 2026. XEN1701 targets NaV1.7, a sodium channel with strong genetic validation as a critical mediator of pain signals. A selective NaV1.7 inhibitor could offer powerful, non-opioid pain relief, a holy grail in modern pharmacology. XEN1120 applies the KV7 mechanism, already validated by azetukalner in epilepsy, to the field of pain.

This multi-pronged strategy showcases a company building not just a single product, but a platform based on its core scientific strengths. The company is also advancing a preclinical NaV1.1 program for Dravet syndrome and is collaborating with Neurocrine Biosciences on another epilepsy candidate, NBI-921355. To support its global ambitions, Xenon has also engaged with Japan’s Pharmaceutical and Medical Devices Agency (PMDA), enrolling Japanese patients in its X-TOLE3 study to facilitate a potential regulatory submission in that key market. As the world watches for the imminent epilepsy data, Xenon's financial health and burgeoning pipeline suggest its story is just beginning.